Sriram, Venkataraman

IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance

Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 418

Targeting TREM2 on tumor-associated macrophages enhances immunotherapy

Binnewies, M., Pollack, J. L., Rudolph, J., Dash, S., Abushawish, M., Lee, T., Jahchan, N. S., Canaday, P., Lu, E., Norng, M., et al. (2021) · Cell Reports

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 365

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab

Lindauer, A., Valiathan, C., Mehta, K., Sriram, V, de Greef, R., Elassaiss-Schaap, J., & de Alwis, D. (2017) · CPT: Pharmacometrics & Systems Pharmacology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 120